Both companies are now under the Norstella umbrella.
Evaluate announced the acquisition of J+D Forecasting, a provider of forecasting solutions focused on the pharmaceutical and life sciences industry.
The move will bring J+D under the Norstella umbrella, the parent company of Evaluate. The parent company also includes Citeline, MMIT, Panalgo, and The Dedham Group. Norstella works to bring therapies to patients and provide insights to pharmaceutical companies during the drug development life cycle.
As part of Norstella, Evaluate provides companies in the life sciences industry with data, insights, and intelligence related to high-value investments for treatments.
In a press release sent to Pharmaceutical Executive, Norstella CEO Mike Gallup said, “We are delighted to welcome the J+D Forecasting team to the Norstella family. Their expertise in developing bespoke forecasting models and innovative, intuitive solutions will provide our customers with an even wider breadth of expertise and cutting-edge insight. The addition of these capabilities significantly boosts our ability to help achieve our mission of smoothing the path of life-saving therapies from pipeline to patient.”
According to the press release, Norstella plans to implement J+D’s forecasting models to improve its forecasting portfolio. The company also plans on using generative AI programs to analyze the data and create comprehensive solutions.
In the same press release, J+D CEO and founder David James said, “The need for high quality forecasting to support decision making in the pharmaceutical and biotech space has never been higher. Bringing together two of the most respected forecasting providers in the industry provides huge opportunities for our customers and I am looking forward to working with the Evaluate team and Norstella to bring innovative solutions to the market.”
In the press release, Evaluate states that this acquisition will provide them with the ability to provide better forecasts related to market size, growth in key indications, and demand for new technologies.
(Jan. 10, 2024); Norstella; Evaluate Announces Acquisition of J+D Forecasting; press release
Young & Partners Pharmaceutical Executive Summit 2024: Brave New World – Where Are We Heading?
October 23rd 2024Peter Marks, director, Center for Biologics Evaluation and Research, FDA, presented the keynote presentation on the future of gene therapy as part of the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.